Structure Therapeutics Inc. Sponsored ADR $GPCR Stock: Jefferies Financial Group Inc. Grows Holdings

Jefferies Financial Group Inc. grew its position in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) by 201.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 122,322 shares of the company’s stock after purchasing an additional 81,697 shares during the period. Jefferies Financial Group Inc. owned approximately 0.18% of Structure Therapeutics worth $3,825,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Squarepoint Ops LLC boosted its position in shares of Structure Therapeutics by 454.5% in the second quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock worth $6,740,000 after buying an additional 102,929 shares during the period. Wellington Management Group LLP grew its position in shares of Structure Therapeutics by 1.6% during the second quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after buying an additional 119,146 shares in the last quarter. Orbimed Advisors LLC grew its holdings in Structure Therapeutics by 27.0% during the 1st quarter. Orbimed Advisors LLC now owns 1,475,403 shares of the company’s stock worth $71,114,000 after acquiring an additional 313,600 shares in the last quarter. Handelsbanken Fonder AB acquired a new position in Structure Therapeutics in the second quarter worth about $1,041,000. Finally, SEB Asset Management AB acquired a new position in shares of Structure Therapeutics in the 1st quarter worth approximately $11,811,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

GPCR has been the topic of a number of research reports. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a report on Friday, August 7th. Weiss Ratings upgraded Structure Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Wednesday, November 4th. HC Wainwright reaffirmed a “buy” rating on shares of Structure Therapeutics in a research note on Thursday. Citizens Jmp reaffirmed a “market outperform” rating and set a $110.00 target price on shares of Structure Therapeutics in a report on Wednesday, September 9th. Finally, Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Structure Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Stock Down 5.3%

Shares of Structure Therapeutics stock opened at $19.84 on Friday. Structure Therapeutics Inc. Sponsored ADR has a 12 month low of $18.70 and a 12 month high of $94.90. The business has a fifty day simple moving average of $28.43 and a 200-day simple moving average of $46.40.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.15). As a group, equities research analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -2.05 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics is a clinical-stage biopharmaceutical company developing medicines for metabolic and other chronic diseases. Its research approach uses structural biology and computational methods to identify and design small-molecule drug candidates. The company’s pipeline includes aleniglipron, an oral small-molecule GLP-1 receptor agonist being developed for obesity and related metabolic conditions. Structure Therapeutics is also advancing other drug candidates targeting biological pathways associated with metabolic disease.